Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01043913
Recruitment Status : Completed
First Posted : January 7, 2010
Last Update Posted : January 7, 2010
Information provided by:
Faculdade de Medicina do ABC

Brief Summary:
The investigators hypothesize that Guaraná, a native plant from the Amazon, might improve chemotherapy-induced fatigue in breast cancer patients undergoing treatment. In order to assess this, the investigators randomized patients to either guaraná extract or to placebo, switching the assigned treatment mid-term through the cycles of Chemotherapy.

Condition or disease Intervention/treatment Phase
Signs and Symptoms Neoplasms Neoplasms by Site Fatigue Breast Neoplasms Breast Diseases Drug: Guarana extract Phase 2

Detailed Description:

The aim of this study is evaluate the favourable effects of Guaraná in quality of life and Fatigue in patients undergoing Chemotherapy treatment for Breast Cancer. After approval by our Institutional Review Board, we included consenting patients with a histological diagnosis of Breast Cancer for whom Chemotherapy was indicated.

Patients who agreed to participate in the study were submitted initially to a screening interview with the Brief Fatigue Inventory questionnaire from MD Anderson. If the patient presented with a severe fatigue, anemia (HB<11.0), hypothyroidism or psychiatric disorders she was excluded. If she presented with a mild or moderate fatigue the follow up continued and the patient was assessed 21 days later after her first cycle of chemotherapy with the same questionnaire. If an increase in fatigue levels occurred from mild to moderate, mild to severe or moderate to severe the patient was randomly assigned to receive either Guaraná 50mg or a placebo p.o. q12 for 21 days. At this moment the patient answered a General questionnaire, FACIT-F, FACIT-ES, HADS, Pittsburgh Sleep Quality Index and Chalder Fatigue Questionnaire (Day 1).

After the second cycle of chemotherapy the patient underwent a "wash out" period of 7 days without any intervention, and after that period she received placebo or Guaraná according to the cross over design after answering for the second time the questionnaires above (Day 29) and also the Common Terminology Criteria for Adverse Events v3.0 (CTCAE). After 21 days (Day 42) she was assessed again with the same questionnaires used in the second interview.

The patient's cancer diagnosis, treatment history, concurrent medication was recorded during the pretreatment and The Brief Fatigue Inventory was answered before each assessment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study
Study Start Date : February 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Paullinia
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Guaraná extract 50mg q12 hours
Guaraná extract pills of 50mg q12 hours for 21 days
Drug: Guarana extract
Guarana extract 50mg q12 hours for 21 days
Other Name: Paullinia Cupana
Placebo Comparator: Placebo 1 tab q12 hours
Placebo pills 1 tab q12 hours for 21 days
Drug: Guarana extract
Guarana extract 50mg q12 hours for 21 days
Other Name: Paullinia Cupana

Primary Outcome Measures :
  1. Fatigue improvement between the baseline to D21 or from D21 to D42 measured by Chalder Fatigue Scale, FACT-F and FACT-ES questionnaires [ Time Frame: 42 days ]

Secondary Outcome Measures :
  1. To access the quality of life between the baseline to D21 or from D21 to D42 measured by FACT-F and FACT ES questionnaires [ Time Frame: 42 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological diagnosis of Breast Cancer
  • Patients undergoing Chemotherapy (First Cycle)
  • 18 years old or older

Exclusion Criteria:

  • Hypothyroidism
  • Clinical Depression
  • Prior Chemotherapy
  • Anemia
  • Unable to sign informed consent
  • Severe Fatigue

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01043913

Faculdade de Medicina do ABC
Santo Andre, SP, Brazil, 09060650
Sponsors and Collaborators
Faculdade de Medicina do ABC
Study Director: Auro D Giglio, MD, PhD Faculdade de Medicina do ABC
Principal Investigator: Maira P Oliveira Campos, MD Faculdade de Medicina do ABC

Publications of Results:
Other Publications:
Responsible Party: Auro Del Giglio, MD, PhD, ABC Foundation School of Medicine Identifier: NCT01043913     History of Changes
Other Study ID Numbers: mairapaschoin
First Posted: January 7, 2010    Key Record Dates
Last Update Posted: January 7, 2010
Last Verified: November 2009

Keywords provided by Faculdade de Medicina do ABC:
Breast Neoplasms
Quality of Life

Additional relevant MeSH terms:
Breast Neoplasms
Signs and Symptoms
Breast Diseases
Neoplasms by Site
Skin Diseases